Jaguar Health, Inc.
26.7.2021 14:31:52 CEST | ACCESS Newswire | Press release
Registration link for webcast appears below
SAN FRANCISCO, CA / ACCESSWIRE / July 26, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) announced today that an Innovators with Jane King interview of Lisa Conte, the company's founder, president, and CEO, will be aired during an investor webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to provide business updates for Jaguar, Napo Pharmaceuticals, Inc. (Jaguar's wholly owned subsidiary), and the Italian subsidiary of Napo Pharmaceuticals, Napo EU S.p.A., which, with Dragon SPAC S.p.A., recently announced the closing of the financing of Dragon SPAC for gross proceeds of approximately 8,830,000 euros. The registration link for the webcast appears below.
Participation Instructions for Webcast
When: Thursday, July 29, 2021, at 8:30 AM Eastern Time
Participant Registration & Access Link: Click Here
About Jaguar Health, Inc., Napo Pharmaceuticals, Inc. & Napo EU S.p.A.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. Napo Pharmaceuticals' wholly owned Italian subsidiary, Napo EU S.p.A., focuses on expanding crofelemer access in Europe and is the named target of Dragon SPAC S.p.A.
For more information about Jaguar, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo EU, visit www.napoeu.com.
About Mytesi®
Mytesi® (crofelemer delayed release tablets) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that an investor webcast will take place July 29, 2021. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
CONTACT:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View source version on accesswire.com:
https://www.accesswire.com/656646/Jaguar-Health-Announces-that-Innovators-with-Jane-King-Interview-with-Lisa-Conte-will-Air-During-Jaguar-Investor-Webcast-on-Thursday-July-29-2021-at-830-AM-Eastern-to-Provide-Business-Updates
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Loar Holdings Inc. Reports Q4 2025 and Full Year 2025 Record Results, and Upward Revisions to Full Year 2026 Outlook26.2.2026 14:30:00 CET | Press release
WHITE PLAINS, NY / ACCESS Newswire / February 26, 2026 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our"), reports record results for the fourth quarter and full year of 2025 and upward revisions to the full year 2026 outlook. "As we close the year, I am pleased to report that Loar once again delivered record results across key financial metrics, including Net Sales, Adjusted EBITDA, and Adjusted EBITDA Margin," said Dirkson Charles, Loar CEO and Executive Co‑Chairman of the Board of Directors. "Driven by favorable end‑market dynamics and disciplined execution across the organization, our team delivered strong operating performance while advancing our long‑term value creation strategy. These results underscore the scalability and resilience of our business model and reinforce Loar's position as a leading aerospace and defense component supplier. We also successfully completed the acquisitions of LMB Fans & Motors and Harper Engineering, further strengthening
U.S. Polo Assn. Returns as Official Apparel and Jersey Sponsor of the 2026 Dubai Polo Gold Cup for Third Consecutive Year26.2.2026 13:00:00 CET | Press release
WEST PALM BEACH, FL AND DUBAI, UAE / ACCESS Newswire / February 26, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly served as the Official Apparel and Jersey Sponsor of the 2026 Dubai Polo Gold Cup, held January 28 through February 14 at the renowned Al Habtoor Polo Club in Dubai, United Arab Emirates.Dubai Wolves by Thera with their trophy on stage at the Dubai Polo Gold Cup 2026 at the Al Habtoor Polo Club Photo Credit: Margarita Crotto Now marking its third consecutive year supporting the prestigious tournament, U.S. Polo Assn. provided custom performance jerseys to participating teams, apparel for event staff, and exclusive player prizes for the finalists. Spectators joined in the excitement during the traditional divot stomp with a special U.S. Polo Assn. cap giveaway, adding a spirited fan moment to the two-week competition in the UAE. The 2026 Dubai Polo Gold Cup Final delivered an electrifying showdown of world-renowned pl
Innovation Holds Key to Future Growth, New Research from Ipsos, Alchemy-RX and Market Logic Finds26.2.2026 10:00:00 CET | Press release
Global organisations are doubling down on innovation and consumer understanding, as they look to grow revenues in the next three years. LONDON, UK / ACCESS Newswire / February 26, 2026 / A new study, Innovation Reignited: C-Suite insights on the state of innovation, from Ipsos, Alchemy-RX and Market Logic reveals that innovation is rapidly becoming the cornerstone of corporate growth strategies worldwide. According to the findings of the survey of C-Suite executives, 82% of companies expect innovation to drive growth strategy. Still, only the most ambitious leaders (33%) anticipate this will account for more than 20% of revenue in the next three years. However, with respondents reporting that less than 75% of innovation launches meet all their launch goals, the risk of missing ambitious growth targets is significant for those who do not optimise their innovation processes. Deeper customer understanding is key While the need to adopt a customer-centric approach to every stage of innovat
Telestream Advances Production-Ready AI Across Its Product Portfolio26.2.2026 09:00:00 CET | Press release
New AI capabilities drive smarter automation, enriched metadata, and assisted workflow design for live and file-based workflows on-premises and in the cloud NEVADA CITY, CA / ACCESS Newswire / February 26, 2026 / Telestream, global leader in media workflow technologies, today announced expanded practical AI enhancements across its Vantage, Vantage Cloud, EDC, Stanza, and Qualify product lines. Building on the foundation introduced with Vantage AI in 2025, Telestream is advancing its production-ready AI workflows, accelerating localization, strengthening quality control, and introducing new AI-assisted workflow design capabilities that connect and unify enterprise operations across on-premises, cloud, and hybrid environments. The latest enhancements reflect a shift from introducing AI features to operationalizing AI across the enterprise, driving measurable workflow impact across ingest, processing, compliance, and delivery. "Last year we introduced Vantage AI as a new foundation for in
Tech "Talent Wars" Are Over as More Companies Prioritize Upskilling, General Assembly Report Finds25.2.2026 15:00:00 CET | Press release
83% of tech recruiters believe company success is more dependent on upskilling employees for AI versus hiring new talent, according to The State of Tech Talent 2026 NEW YORK CITY, NY / ACCESS Newswire / February 25, 2026 / Nearly all technology recruiters (96%) say technical roles are still at least a bit difficult to fill, as most (83%) believe their company's success is now more dependent on upskilling their existing employees for AI rather than hiring external talent, according to The State of Tech Talent 2026, the fourth annual report from AI training provider General Assembly, an LHH brand. "The AI skills gap is growing too fast for companies to hire their way out," said Daniele Grassi, CEO of General Assembly. "Continuous, incremental and role-specific learning is the only way to keep up with the pace of technology change. Growing investment in upskilling reflects leaders' realization that their existing employees bring the business context, institutional knowledge and cultural n
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom